Brenig Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $65M

  • Investors
  • 6

Brenig Therapeutics General Information

Description

Operator of a drug development company intended to utilize an AI/ML approach through clinical candidates across multiple therapeutic areas. The company is redefining the frontier of aging science with a resolute focus on addressing neurodegeneration and translating groundbreaking research into transformative therapies, enabling drug discovery companies to defeat neurodegenerative diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 100 Chestnut Street
  • Suite 300
  • Somerville, MA 02143
  • United States
+1 (818)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 100 Chestnut Street
  • Suite 300
  • Somerville, MA 02143
  • United States
+1 (818)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Brenig Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 23-Jul-2024 $65M Completed Clinical Trials - Phase 1
1. Early Stage VC 22-Apr-2021 Completed Clinical Trials - Phase 1
To view Brenig Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Brenig Therapeutics Patents

Brenig Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025235687-A1 Lrrk2 inhibitors Pending 08-May-2024
AU-2023249498-A1 Lrrk2 inhibitors Active 04-Apr-2022
AU-2023249498-B2 Lrrk2 inhibitors Active 04-Apr-2022
EP-4504722-A2 Lrrk2 inhibitors Pending 04-Apr-2022
EP-4504722-A4 Lrrk2 inhibitors Pending 04-Apr-2022 A61K31/501
To view Brenig Therapeutics’s complete patent history, request access »

Brenig Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayshore Global Management Family Office Minority
New Enterprise Associates Venture Capital Minority
Torrey Pines Investment Venture Capital Minority
BioGeneration Ventures Venture Capital Minority
i2020 Accelerator Accelerator/Incubator Minority
You’re viewing 5 of 6 investors. Get the full list »

Brenig Therapeutics FAQs

  • When was Brenig Therapeutics founded?

    Brenig Therapeutics was founded in 2021.

  • Where is Brenig Therapeutics headquartered?

    Brenig Therapeutics is headquartered in Somerville, MA.

  • What industry is Brenig Therapeutics in?

    Brenig Therapeutics’s primary industry is Drug Discovery.

  • Is Brenig Therapeutics a private or public company?

    Brenig Therapeutics is a Private company.

  • What is Brenig Therapeutics’s current revenue?

    The current revenue for Brenig Therapeutics is .

  • How much funding has Brenig Therapeutics raised over time?

    Brenig Therapeutics has raised $73M.

  • Who are Brenig Therapeutics’s investors?

    Bayshore Global Management, New Enterprise Associates, Torrey Pines Investment, BioGeneration Ventures, and i2020 Accelerator are 5 of 6 investors who have invested in Brenig Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process